The NLRP3 inflammasome inhibitor MCC950 was reported to relieve liver inflammation via polarizing macrophages into M2 phenotype in CCl4-induced liver injury (136) and fibrosis via decreasing plasma and hepatic IL-1β and IL-6 in a mouse model of NASH (133), suggesting the pivotal role of MCC950 in attenuating liver inflammation from various etiologies. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatohepatitis.